Amneal donates hydroxychloroquine sulfate to Texas

Amneal has donated 1 million hydroxychloroquine sulfate tablets to the Texas State Pharmacy, which it said would be directly distributed to hospitals for potential use in treating COVID-19 patients.

“On behalf of the people of Texas, I thank Amneal for this generous donation,” said Texas State Sen. Bryan Hughes, who chairs the Senate’s Committee on State Affairs. “In trying times like these, Americans come together and put others ahead of themselves. Amneal’s donation is a shining example, and it reminds us of how blessed we are to be Americans.”

Hughes added, “I also want to thank the leadership of the Texas Department of Emergency Management, the Texas Health and Human Services Commission, and many professionals at Franklin Scott Conway, who were instrumental in securing this donation.”

“This is a crucial time in the global fight against COVID-19,” Amneal co-CEOs Chirag and Chintu Patel said in a statement. “With an existing supply of hydroxychloroquine sulfate and our ability to quickly accelerate production, we are humbled to be able to assist the hardest hit states and hospitals around the country to benefit as many patients as possible.”

Amneal has donated two million tablets of 200 mg hydroxychloroquine sulfate to New York, and will provide more as needed. The Company also is donating and providing products directly to hospitals across the country.

Hydroxychloroquine sulfate was first synthesized in 1946 and is in a class of medications historically used to treat and prevent malaria.

Amneal’s hydroxychloroquine sulfate tablets are approved by the Food and Drug Administration to treat malaria, rheumatoid arthritis, lupus, childhood arthritis and other autoimmune diseases. Hydroxychloroquine is not FDA approved for the treatment of COVID-19; but it has been identified as a possible treatment for COVID-19,1 and the U.S. government has requested its immediate availability.